Scynexis (SCYX) Non-Current Debt (2016 - 2022)
Scynexis' (SCYX) quarterly Non-Current Debt came in at $34.4 million in Q4 2022, up 19.65% on a YoY basis from $28.7 million in Q4 2021, and up 0.68% quarter-over-quarter from $34.2 million in Q3 2022.
Analysis
Scynexis (SCYX) Non-Current Debt (2016 - 2022) Analysis & Trends
Scynexis (SCYX) has reported Non-Current Debt for 5 consecutive years, with $34.4 million the latest figure, recorded in Q4 2022.
- For the quarter ending Q4 2022, Non-Current Debt rose 19.65% year-over-year to $34.4 million; the trailing twelve-month figure through Dec 2022 stood at $34.4 million (up 19.65% YoY), and the FY2022 full-year result was $34.4 million, up 19.65% from the prior year.
- Non-Current Debt improved to $34.4 million in Q4 2022 per SCYX's latest filing, from $34.2 million in the prior quarter.
- Across five years, Non-Current Debt topped out at $34.4 million in Q4 2022 and bottomed at $7.6 million in Q3 2018.
- Historically, Non-Current Debt has averaged $24.1 million across 3 years, with a median of $28.6 million in 2021.
- The widest YoY moves for Non-Current Debt: up 46.38% in 2018, down 34.91% in 2018.
- Over 3 years, Non-Current Debt stood at $15.1 million in 2018, then surged by 90.59% to $28.7 million in 2021, then grew by 19.65% to $34.4 million in 2022.
- According to Business Quant data, Non-Current Debt over the past three periods registered $34.4 million, $34.2 million, and $33.9 million for Q4 2022, Q3 2022, and Q2 2022 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | 57.30 Bn |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | 26.25 Bn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | 1.99 Bn |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | - |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | 591.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | - |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | 7.29 Bn |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | - |
| 10 | Scynexis | 58.41 Mn | -56.29 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2022 | 34.39 Mn |
| Sep 30, 2022 | 34.16 Mn |
| Jun 30, 2022 | 33.94 Mn |
| Mar 31, 2022 | 33.71 Mn |
| Dec 31, 2021 | 28.75 Mn |
| Sep 30, 2021 | 28.58 Mn |
| Jun 30, 2021 | 28.38 Mn |
| Dec 31, 2018 | 15.08 Mn |
| Sep 30, 2018 | 7.62 Mn |
| Jun 30, 2018 | 9.39 Mn |
| Mar 31, 2018 | 11.16 Mn |
| Dec 31, 2017 | 10.30 Mn |
| Sep 30, 2017 | 11.70 Mn |
| Jun 30, 2017 | 13.10 Mn |
| Mar 31, 2017 | 14.35 Mn |
| Dec 31, 2016 | 14.25 Mn |
| Sep 30, 2016 | 14.17 Mn |